Results 41 to 50 of about 1,329,719 (361)

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide [PDF]

, 2018
The aim of this study is to assess the prevalence of cardiac involvement in hereditary transthyretin-derived (ATTRm) amyloidosis at the time of diagnosis and to determine the diagnostic and clinical value of N-terminal pro-B-type natriuretic peptide (NT ...
Blokzijl, Hans, Hazenberg, Bouke P C, Klaassen, Sebastiaan H C, Nienhuis, Hans L A, Tromp, Jasper, van den Berg, Maarten P, van der Meer, Peter, van Veldhuisen, Dirk J   +7 more
core   +2 more sources

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +1 more source

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Dungu, J, Gibbs, SD, Gilbertson, JA, Gillmore, JD, Hawkins, PN, Lachmann, HJ, McCarthy, CA, Petrie, A, Pinney, JH, Rowczenio, D, Sattianayagam, P, Venner, CP, Wassef, N, Wechalekar, A, Whelan, CJ   +15 more
core   +1 more source

Value of the HFA‐PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis

European Journal of Heart Failure, 2022
The HFA‐PEFF and H2FPEF scores have been developed to diagnose heart failure with preserved ejection fraction (HFpEF), and hold prognostic value. Their value in patients with HFpEF caused by cardiac amyloidosis (CA) has never been investigated.
D. Tomasoni, A. Aimo, M. Merlo, M. Nardi, M. Adamo, Maria Giulia Bellicini, Dario S Cani, M. Franzini, A. Khalil, E. Pancaldi, G. Panichella, A. Porcari, M. Rossi, G. Vergaro, C. Lombardi, G. Sinagra, C. Rapezzi, M. Emdin, M. Metra   +18 more
semanticscholar   +1 more source

Clinical features and predictors of atrial fibrillation in patients with light‐chain or transthyretin cardiac amyloidosis

ESC Heart Failure, 2022
The study aimed to investigate the prevalence, phenotypic characteristics, and predictors of atrial fibrillation (AF) in patients presenting with cardiac amyloidosis (CA) of light‐chain (AL) or transthyretin (ATTR) type.
M. Papathanasiou, A. Jakstaite, Sara Oubari, J. Siebermair, R. Wakili, J. Hoffmann, A. Carpinteiro, T. Hagenacker, A. Thimm, C. Rischpler, L. Kessler, T. Rassaf, P. Luedike   +12 more
semanticscholar   +1 more source

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis

JACC. CardioOncology, 2020
Objectives: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis.
Kathleen W. Zhang, MD, Jennifer Miao, MD, Joshua D. Mitchell, MD, Jose Alvarez-Cardona, MD, Kelsey Tomasek, BS, Yan Ru Su, MD, Mary Gordon, RN, R. Frank Cornell, MD, Daniel J. Lenihan, MD   +8 more
doaj   +1 more source

Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.

PLoS ONE, 2022
BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy, Liliana Szabo, Zoltan Pozsonyi, Ibolya Csecs, Attila Toth, Ferenc Imre Suhai, Csilla Czimbalmos, Andrea Szucs, Anna Reka Kiss, David Becker, Bela Merkely, Hajnalka Vago   +11 more
doaj   +1 more source

Uncovering the Mechanism of Aggregation of Human Transthyretin. [PDF]

, 2015
The tetrameric thyroxine transport protein transthyretin (TTR) forms amyloid fibrils upon dissociation and monomer unfolding. The aggregation of transthyretin has been reported as the cause of the life-threatening transthyretin amyloidosis.
Cascio, Duilio, Eisenberg, David S, Jiang, Lin, Johnson, Lisa M, Liang, Wilson Y, Riek, Roland, Ruchala, Piotr, Saelices, Lorena, Sawaya, Michael R, Whitelegge, Julian   +9 more
core   +2 more sources

Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis

Journal of Nuclear Cardiology, 2022
Introduction Transthyretin (ATTR) amyloidosis is responsible for the majority of cardiac amyloidosis (CA) cases and can be reliably diagnosed with bone scintigraphy and the visual Perugini score.
L. Kessler, P. Fragoso Costa, D. Kersting, W. Jentzen, Manuel Weber, P. Lüdike, A. Carpinteiro, Sara Oubari, T. Hagenacker, A. Thimm, T. Rassaf, K. Herrmann, M. Papathanasiou, C. Rischpler   +13 more
semanticscholar   +1 more source

Rapid decline in ejection fraction and persistent elevation of troponin associated with cardiac amyloidosis

SAGE Open Medical Case Reports, 2020
Cardiac amyloidosis is an increasingly recognized cause of heart failure. It remains underdiagnosed despite a significant morbidity and mortality rate. The mean survival in patients with cardiac amyloidosis is less than 1 year in untreated primary light ...
Temidayo Abe, Eric Y Chang, Gabrielle De Allie, Taiwo Ajose, Chukwuemeka Nwokike, Nicolas Bakinde   +5 more
doaj   +1 more source